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INTRODUCTION: Our aim is to observe the evolution of HCV epidemic in Belgium. The evolution over a 10 year period (1992-2003) of 
the epidemiological profile of 1726 newly diagnosed HCV patients in Belgium had been previously published (J Med Virol 2005, 76 : 503-510). We 
extended this analysis over 5 additional years (until 12/2007) on 2884 pts.
Number of newly HCV diagnosed pts [1992-2007] Evolution with time of HCV infecting genotypes
Evolution with time of HCV Risk Factors
The distribution of risk factors (transfusion, drug use, 
and, surprinsingly, invasive medical procedures 
[IMP]) significantly differed between different 
geographical areas in Belgium. 
The number of new pts increased linearly with time until 2003 (r=0.97) with a 
maximum of 300 newly presenting pts/year), but after 2003, this number 
decreased rapidly (158 in 2008). Cumulated cases increased.
The rate of newly presenting pts infected by Transfusion before 1990 decreased, but only by 1,9%/yr (reaching always the high figure of 20% of newly 
presenting pts in 2008). The proportion of Intravenous Drug Users increased by 2%/yr (40% in 2008). Pts presenting Undefined risks factors increased by 
0,6%/yr (25% in 2008), probably in relation with migration in Belgium of pts originating from countries where HCV is highly prevalent.
CONCLUSION :  The epidemic continues to evolve with the same trends observed during our previous study : whereas the rate of newly 
presenting patients infected by transfusion before 1990 is decreasing, it was still concerning 20% of patients in 2008. Genotype 1a, 3 and 4 increased with 
time contrarily to genotype 1b which significantly decreased.
 After reaching a top in 2003, the number of newly HCV diagnosed patient is now decreasing in Southern Belgium.
 Some loco-regional variations have been observed.
Such analyses are useful for evaluating the epidemiological changes of C virus infection and for anticipating the future economical costs of HCV treatment 
in the next few years.
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New patients diagnosed / year
Cumulated cases
There was a singificant evolution with time of infecting HCV genotypes. Significant linear decrease of
2% /yr in the frequency of genotype 1b, is counterbalanced by a significant increase of genotype 1a
(0,52%/yr), 3 (0.74%/yr) and 4 (0,75%/yr). Between 1992 and 2007, the evolution of genotypes was as
follows : genotype 1b [66% to 36%], genotype 1a [3% to 11%], genotype 3 [10% to 21%] and genotype
4 [5% to 16%].
Parameters HUY LIEGE VERVIERS WAREMME p
Age (<50) 51.01 41.56 44.74 50 NS
Sex (M) 44.3 54.39 52.83 53.13 NS
Transfusion 35.57 23.3 21.56 10.94 0.0004
IV DU 11.41 18.46 7.82 6.25 <0.0001
Dialysis 3.36 1.88 1.35 1.56 NS
Other 8.72 12.14 15.09 10.94 NS
Sexual 0.67 0.89 1.62 3.13 NS
IMP 3.36 3.36 12.94 1.56 <0.0001
Surgery 0 0.79 0.54 0 NS
Loco-regional variations
MATERIAL & METHODS : The data base contained 2884 pts found HCV-PCR positive between 1992 and 2007. For all patients, the 
following parameters were available : age, sex, date of birth, date of first HCV-PCR positive, place of residence, ethnic origin. The genotype has 
been identified for 1585 patients (55%), whereas a risk factor of HCV acquisition could be documented for 1389 patients (48%).The postal code 
of residence place of HCV patients in Liège and suburbs was documented for 1719 HCV patients (60%). The evolution with time of genotypes and 
risk factors was calculated using a linear regression model (Y= aX + b) where “a” is the slope representing the annual variation of the considered 
parameter (risk factors and genotypes). The annual rate of variation was expressed in %.
